MarioSznolMD

Oncology • New Haven, CT

Hematologic Oncology, Melanoma

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Join to view full profile

Dr. Sznol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sznol's full profile

Already have an account?

Office
333 Cedar Street, WWW222
New Haven, CT
New Haven, CT 06520
Phone+1 203-200-6622

Fax+1 203-785-3788

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1985 - 1987
Baylor College of MedicineResidency, Internal Medicine, 1982 - 1985
Baylor College of MedicineClass of 1982

Certifications & Licensure

CT State Medical License 2000 - 2025
MD State Medical License 1987 - 2001
TX State Medical License 1983 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Join now to see all

Clinical Trials

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Start of enrollment: 1996 Oct 01
Terminated
Phase 1
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors Start of enrollment: 1998 May 01
Completed
Phase 1
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy Start of enrollment: 1999 Aug 01
Completed
Phase 1
3-AP in Treating Patients With Advanced Cancer Start of enrollment: 2000 May 01
Completed
Phase 1
VNP20009 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 May 01
Completed
Phase 1
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 1
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2001 Mar 01
Completed
Phase 1
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome Start of enrollment: 2002 Apr 01
Completed
Phase 1
VNP40101M in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
3-AP in Treating Patients With Advanced Prostate Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 2
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
3-AP and Cytarabine in Treating Patients With Hematologic Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 1
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies Start of enrollment: 2003 Jun 01
Completed
Phase 1
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2005 Jul 01
Completed
Phase 1
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy Start of enrollment: 2006 Feb 01
Terminated
Phase 1
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) Start of enrollment: 2009 Jul 01
Completed
Phase 1
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Start of enrollment: 2010 Sep 28
Completed
Phase 1
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection Start of enrollment: 2022 Nov 08
Terminated
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

9288 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27
30 citations
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
Shlomit Jessel, Sarah A Weiss, Matthew Austin, Amit Mahajan, Katrina Etts
Frontiers in Oncology. 2022-01-01
970 citations
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Gwendolyn Fyfe, Richard I. Fisher, Steven A. Rosenberg, Mario Sznol, David Parkinson
Journal of Clinical Oncology. 1995-03-01

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

Chair - Hematologic Malignancies and CAR-T Cell Therapy. Hematologic Malignancies and CAR-T Cell Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Case Presentations. Managing Immune-Related Adverse Events: The Challenge to Maximize the Risk/Benefit Ratio (A Case-Based Discussion)
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Chair - Basic Principles of Immunotherapy. Basic Principles of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Immunotherapy Basics. Basic Principles of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Join now to see all

Press Mentions

Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024
Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 4th, 2022
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to Its Scientific Advisory BoardMarch 24th, 2022
Join now to see all